跳至主要内容
临床试验/NCT01640743
NCT01640743已完成不适用

Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation: a Randomized Study

Fondazione IRCCS Policlinico San Matteo di Pavia1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2010年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
58
试验地点
1
主要终点
Effect of different treatments on absolute and percentual number of regulatory T cells

研究概览

简要总结

The objective of the study will be to evaluate the effect of different therapeutic immunosuppressive strategies currently employed in common clinical practice on regulatory T lymphocytes and to verify the hypothesis that the association of thymoglobulins - mTOR inhibitors - small doses of Tacrolimus not only represents a safe anti-rejection therapy but it can also lead to mid-term formation of a high amount of regulatory T cells and, consequently, a high grade of tolerance.

详细描述

Immune response is mediated by the interaction between antigen-presenting cells (APC), CD4+ helper T cells (Th) and regulatory T cells (Treg), a subpopulation of CD4+ T cells which intensively expresses IL-2 receptor (CD25) and FoxP3 transcription factor. Treg cells contribute maintaining tolerance by suppressing immune response to normal or tumour self-antigens. Treg cells originate in the thymus during ontogenesis and represent approximately 10% of peripheral CD4+ cells. All effector T lymphocytes generate in the thymus at the early stages of life and evolve through the production of new T lymphocytes as well as through antigen-induced expansion of virgin (naive) peripheral T lymphocytes which convert to "memory" T lymphocytes and lie in peripheral lymphoid organs (17). Mature T lymphocytes constitute 70-80% of normal peripheral blood lymphocytes, 30-40% of lymph nodes cells and 20-30% of splenic lymphoid cells.

T lymphocytes are primary effectors of cell-mediated immunity and differentiate into a subpopulation of CD8+ cytotoxic T lymphocytes which are able to lyse foreign cells or virus infected host-cells and a subpopulation of CD4+ T lymphocytes with a regulating activity on T and B lymphocytes and monocytes, through the production of cytokines and cell-to-cell contact.

Treg lymphocytes play a central role among CD4+ cells in balancing tolerance and immunity, as they are responsible for maintaining peripheral tolerance through the control of self-reactive T cells which escaped thymic deletion (19). Studies have in fact demonstrated that whether on one side a defect in their development or activity can lead to serious autoimmune diseases, an excessive immunosuppression mediated by these cells stimulates, on the other side, an immunodeficient condition also towards antigens produced by neoplastic cells favouring, as a consequence, tumour growth.

Treg lymphocytes represent approximately 10% of all CD4+ T cells present in the thymus, peripheral blood and lymphoid tissues; they consist of various populations which differ in terms of particular cell-surface molecules expression and the production of diverse cytokines, but share a common scarce response to antigenic stimulation and an immunosuppressive activity.

The best characterized Treg lymphocytes are the so called "natural occurring Tregs" (nTregs), a sub-group of CD4+ T cells which originates and develops in the thymus during T-cellular maturation process and is afterwards normally present in peripheral blood with the function of controlling self-antigens and preventing autoimmune diseases. These lymphocytes are characterized by the constitutive expression of CD-25 (interleukin-2 receptor α chain), Foxp3 transcription factor (specific to these cells and implied in the development control within the thymus), CTLA-4, GITR and LAG-3 surface molecules as well as TGF-β cytokine, which is present in great quantity on cellular surface and is fundamental to their functioning.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female aged from 18 to 75 years
  • Transplanted patients from cadaveric donors
  • Patients who has given written informed consensus

排除标准

  • Legally unable patients
  • Patients who have been participated to others studies in the last 3 months
  • Addicted to alcohol or smoking

研究组 & 干预措施

Evertwist 1

Experimental

Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).

干预措施: Tacrolimus + Methylprednisolone (Drug)

Evertwist 2

Experimental

Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).

干预措施: Tacrolimus + Everolimus + Methylprednisolone (Drug)

结局指标

主要结局

Effect of different treatments on absolute and percentual number of regulatory T cells

时间窗: 12 months

Comparison of absolute and percentual number of high Treg and FoxP3+ Treg cells in one year post-transplant patients under treatment with different immunosuppressive therapies.

次要结局

  • Influence of Treg cell number on renal function and incidence of rejection, death, infection events and cardiovascular diseases.(24 months)

研究者

发起方
Fondazione IRCCS Policlinico San Matteo di Pavia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Carmelo Libetta

MD

Fondazione IRCCS Policlinico San Matteo di Pavia

研究点 (1)

Loading locations...

相似试验

Effect of Different Therapeutic Strategies on... | 临床试验